Malone Commercial Brokers is pleased to offer for lease up to 75,000± SF at a brand-new medical campus within the Rock Row development in Westbrook.
Rock Row is situated right on the town line with Portland, with Interstate 95 marking the property’s eastern boundary. Early tenants in the 56+ AC development, including Market Basket and outdoor retailer REI, are already thriving thanks to their convenient location to hundreds of thousands of residents and workers. When complete, Rock Row will contain 1,000 residential units, 400,000 SF of loft and Class-A workspace, 300,000 SF of retail services, and two daycare centers.
The Medical Campus—a total of 165,000± SF—will be anchored by New England Cancer Specialists, a member of the world-renowned Dana-Farber Cancer Care Collaborative. The campus will serve as an international model of leading edge, inte grated cancer care and research. 75,000± SF across the 3rd, 4th and 5th floors are available for lease, subdividable down to 5,000± SF. These spaces can be delivered vanilla shell or build-to-suit. Planned parking will be free for medical staff and patients.
Spaces will be available in 2023. Lease rates provided upon request.
The Rock Row Medical Campus is listed by Mark Malone, CCIM,
of Malone Commercial Brokers in Portland. Please contact Mark at 207-773-6000; 207-233-6000 or mark@malonecb.com.
Visit malonecb.com to learn more about Maine commercial properties for sale or lease.
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less